Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

NAMPT encapsulated by extracellular vesicles from young adipose-derived mesenchymal stem cells treated tendinopathy in a "One-Stone-Two-Birds" manner.

Wu G., Su Q., Li J., Xue C., Zhu J., Cai Q.

Animal Study on Tendon Injury, published in J Nanobiotechnology (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Nanobiotechnology (2023)
Country
England
Reported sample size
—
Source database
PubMed
PMID
36604715
PMCID
PMC9814467
DOI
10.1186/s12951-022-01763-5
Citations
23

Abstract (original English)

Background Tendinopathy is the leading sports-related injury and will cause severe weakness and tenderness. Effective therapy for tendinopathy remains limited, and extracellular vesicles (EVs) derived from adipose tissue-derived mesenchymal stem cells (ADMSCs) have demonstrated great potential in tendinopathy treatment; however, the influence of aging status on EV treatment has not been previously described. Results In this study, it was found that ADMSCs derived from old mice (ADMSC old ) demonstrated remarkable cellular senescence and impaired NAD+ metabolism compared with ADMSCs derived from young mice (ADMSC young ). Lower NAMPT contents were detected in both ADMSC old and its secreted EVs (ADMSC old -EVs). Advanced animal experiments demonstrated that ADMSC young -EVs, but not ADMSC old -EVs, alleviated the pathological structural, functional and biomechanical properties in tendinopathy mice. Mechanistic analyses demonstrated that ADMSC young -EVs improved cell viability and relieved cellular senescence of tenocytes through the NAMPT/SIRT1/PPARγ/PGC-1α pathway. ADMSC young -EVs, but not ADMSC old -EVs, promoted phagocytosis and M2 polarization in macrophages through the NAMPT/SIRT1/Nf-κb p65/NLRP3 pathway. The macrophage/tenocyte crosstalk in tendinopathy was influenced by ADMSC young -EV treatment and thus it demonstrated "One-Stone-Two-Birds" effects in tendinopathy trea

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMiceExtracellular VesiclesMesenchymal Stem CellsSirtuin 1TendinopathyCytokinesNicotinamide Phosphoribosyltransferase

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research